Oculis Holding AG (OCS) Stock Analysis

Q: What is the OCS stock price target?

Take-profit $41.21 (+53.2% upside). Prior stop was $25.07.

Q: Is OCS overvalued or undervalued?

Oculis Holding AG trades at a P/E of N/A (forward -12.3). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about OCS?

15 analysts cover OCS with a consensus score of 4.3/5. Average price target: $47.

Range Bound setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Sell if holding. Engine safety override at $26.90: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.

$26.90+53.2% A.UpsideScore 5.4/10#46 of 158 Biotechnology

Stop $25.07Target $41.21(analyst − 13%)A.R:R 6.0:1

Analyst target$47.37+76.1%10 analysts

$41.21our TP

$26.90price

$47.37mean

$56

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.9 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-12.3

Mkt Cap$1.5B

EV/EBITDA-16.2

Profit Mgn0.0%

ROE-73.5%

Rev Growth13600.0%

Beta0.21

DividendNone

Rating analysts15

Quality Signals

Piotroski F3/9

Options Flow

P/C0.03bullish

IV66%elevated

Max Pain$35+30.1% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.915%0.28

Growth5.015%0.75

Momentum4.410%0.44

Sentiment7.910%0.79

Insider Activity5.010%0.50

Peer Rank5.210%0.52

Technical Setup6.45%0.32

Risk Profile6.75%0.34

Catalyst2.55%0.13

Overall (Σ contributions)5.42

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Moat

5.0

Current Ratio

7.0

Cash-burning: FCF -3643% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 11 days

GatesMomentum 4.4<4.5EARNINGS PROXIMITY 11d<=14d (soft)A.R:R 6.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

47 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $25.85Resistance $29.43

Price Targets

$25

$41

A.Upside+53.2%

A.R:R6.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.9 < 4.0)

! Momentum score 4.4/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-05-11 (11d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is OCS stock a buy right now?

Sell if holding. Engine safety override at $26.90: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $25.07. Score 5.4/10, moderate confidence.

What is the OCS stock price target?

Take-profit target: $41.21 (+53.2% upside). Prior stop was $25.07. Stop-loss: $25.07.

What are the risks of investing in OCS?

Quality below floor (1.9 < 4.0).

Is OCS overvalued or undervalued?

Oculis Holding AG trades at a P/E of N/A (forward -12.3). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about OCS?

15 analysts cover OCS with a consensus score of 4.3/5. Average price target: $47.

What does Oculis Holding AG do?Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic,...

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.